R R I T S , L E V E N e t a l E L T R O M B O P A G I N W A S / X L T P A T I E N T S 1 G E R R I T S , L E V E N e t a l E L T R O M B O P A G I N W A S / X L T P A T I E N T S G E R R I T S , L E V E N e t a l E L T R O M B O P A G I N W A S / X L T P A T I E N T S 3 G E R R I T S , L E V E N e t a l E L T R O M B O P A G I N W A S / X L T P A T I E N T S INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency and platelet disease,
characterized by a combination of thrombocytopenia with small platelets, eczema, recurrent infections and a high incidence of autoimmunity and malignancy. 1 Whereas the immune defects vary in clinical severity, the thrombocytopenia is a universal and almost always profound characteristic of the disease.
WAS is caused by mutations of the WAS gene encoding the WAS protein (WASP), exclusively expressed in hematopoietic cells and involved in cell signaling and cytoskeleton reorganization. [2] [3] [4] Although the gene responsible for WAS has been identified, the cause of thrombocytopenia is not fully known. WASP deficiency appears to affect both platelet production and consumption. 5 Some patients develop autoimmune thrombocytopenia, resulting in a more severe degree of thrombocytopenia and bleeding and lesser effectiveness of platelet transfusions. 6 Point mutations in exons 1 and 2 of the WAS gene typically result in X-linked thrombocytopenia (XLT), a milder form of the disease usually without infections or eczema. 7;8 WAS and XLT represent polar ends of the disease spectrum, although there is actually a continuum including intermediate forms.
XLT patients have profound thrombocytopenia and bleeding but not the immune dysregulation seen in patients with WAS. Treatment of the thrombocytopenia in WAS/XLT has primarily included splenectomy or stem cell transplantation.
Bleeding occurs in the majority (84%) of patients with WAS/XLT, including petechiae or purpura (78%), epistaxes (16%) and hematemesis and melena (28%). 9 Other significant bleeding is present in 5% of patients, including bleeding from the umbilical stump, postsurgical bleeding, posttraumatic bleeding, testicular hemorrhage and subconjunctival hemorrhage. Severe, lifethreatening bleeding episodes, such as gastrointestinal and intracranial hemorrhage, occur in up to 30% of patients with WAS/XLT and cause death in 4-10% of these patients. 9, 10 Expression of the major platelet membrane glycoproteins in WAS patients is normal. 11 However, platelet function in WAS/XLT has been very difficult to evaluate because of both the reduced platelet count and size, which affect all platelet function assays except flow cytometry. 12 Attempts to measure platelet function in WAS patients have resulted in highly variable
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outcomes: an absence of platelet aggregation in response to multiple agonists, 13 normal aggregation 14 and a slightly enhanced platelet response. 15 In another study, when only WASPdeficient platelets with normal size were included in the analysis by electronic gating, flow cytometry results showed that the number of glycoprotein (GP) IIb-IIIa molecules per platelet was lower in platelets from WAS patients compared to healthy controls and agonist-induced expression of GPIIb-IIIa, P-selectin and CD63 was diminished in WAS platelets, suggesting that there may be a defect in activation. 16 Two studies by Shcherbina et al. showed increased expression of phosphatidylserine on the surface of circulating platelets and an increase in platelet-derived microparticles in the plasma of WAS/XLT patients, raising the possibility that these features explain or at least contribute to the reduced platelet lifespan and size in this disease.
17;18
To better understand the pathogenesis of bleeding in WAS/XLT, the present study examined platelet activation by whole blood flow cytometry in WAS/XLT patients compared to healthy age-matched controls. Platelet activation markers were corrected for platelet size difference because of the microthrombocytopenia in WAS/XLT. In addition, the present study tested a thrombopoietin receptor agonist (eltrombopag) as a potential novel treatment for the thrombocytopenia of WAS/XLT. Platelet counts, platelet production, platelet activation and bleeding diathesis were examined before and after eltrombopag treatment. Platelet production in WAS/XLT patients was compared to that in pediatric immune thrombocytopenia (ITP) patients treated with eltrombopag.
METHODS

Subjects
Thirteen patients with WAS/XLT and 8 age-matched healthy controls, or their parents, gave written informed consent in accordance with the Declaration of Helsinki prior to participation in this Weill Cornell Medical College IRB-approved study. Patients were classified as either WAS or XLT based on their clinical history, laboratory testing, and presentation and given a grade based on the Ochs WAS score (Table 1) . 19 Nine patients consented to platelet activation studies which required only additional blood to be drawn at scheduled blood draws. Four of these 9
patients went on to treatment with eltrombopag in the study and 5 WAS/XLT patients only had their platelet activation tested: 3 patients had platelet counts > 100 × 10 9 /L (two of whom had undergone splenectomy), one patient was too small to take tablets, and one patient's parents allowed the blood draw but not treatment with eltrombopag. Eltrombopag (Promacta/Revolade; GlaxoSmithKline) was administered to 8 patients as part of a phase II study (Pathobiology of Thrombocytopenia and Bleeding in Patients with Wiskott-Aldrich Syndrome, NCT00909363).
Male patients between 3 months and 80 years of age with a clinical diagnosis of WAS/XLT and baseline platelet counts <50 × 10 9 /L were eligible to enroll in the treatment study and all eligible patients for whom consent was obtained were enrolled. Eltrombopag (9-75 mg) was administered orally once daily and dosing was adjusted to maintain the platelet count > 50 x 10 9 /L. Blood samples from 3 WAS/XLT patients treated with eltrombopag were studied for platelet activation before and after initiation of treatment. Blood from a fourth WAS/XLT patient treated with eltrombopag was studied for platelet activation but only prior to treatment. Of the other 4 patients who were treated with eltrombopag but did not have their platelet activation studied, 3 patients were in Israel and therefore unavailable for testing, and the 4 th patient could only come to clinic on Fridays and therefore his blood could not be processed and analyzed by flow cytometry within 48 hours. Bone marrow examination was performed in one patient who had been on eltrombopag, while others are being scheduled.
Freshly drawn venous blood from WAS/XLT patients, and from healthy volunteers who had not taken any antiplatelet medications within 7 days before the study, was collected into 4.5 mL
3.2% trisodium citrate and ethylenediaminetetraacetric acid (EDTA) Vacutainers (BD Biosciences). The EDTA sample was used for measurements of platelet counts in a Bayer-Advia automated complete blood count counter immediately after the blood draw and the absolute immature platelet fraction (AIPF) in a Sysmex XE-2100 automated analyzer.
Platelet activation
Less than 10 minutes after blood draw, aliquots of whole blood from the citrate sample were GPIIb-IIIa, P-selectin and CD41, as previously described. 20 Established voltages for forward scatter (FSC) and side scatter (SSC) were used to present platelets in the middle of the dot plot (FSC-SSC). Cells with high FSC-SSC were gated out. A gate was drawn around the platelets and FSC was measured, as previously described.
21
Statistical analysis
Results are stated as mean ± SEM. Data were analyzed using GraphPad Prism, version 5 (San Diego, CA). Two-way ANOVA with Bonferroni post-test was performed to determine differences between the health status of subjects (healthy controls or patients) and agonist treatment and the possible interactions of each. Platelet counts were analyzed with the Student's test for unpaired observations. Results were considered significant if P was less than 0.05.
RESULTS
Patient demographics and clinical characteristics
No difference was observed between the mean age of the 9 WAS/XLT patients who had their platelet activation measured and healthy controls, 6.9 ± 2.7 years (range 0.5 -26) ( Table 1) versus 12.7 ± 4.6 years (range 1.33 -33) (mean ± SEM), respectively (p=0.28). There was no correlation between age and any of the responses in platelet activation assays (data not shown).
Because WAS/XLT is an X-linked disease, 100% of patients were male; 89% of patients were children. Two patients studied for platelet activation had undergone a splenectomy. In the control group, 63% were children and 38% were male. Three patients received eltrombopag (20-75 mg), and had platelet activation markers studied before and after treatment (Table 1) . Control subjects did not take any medications at the time of the study. Platelet counts were 373.8 ± 59.9 × 10 9 /L (mean ± SEM) for healthy controls, whereas, for the 9 WAS/XLT patients who had their platelet activation measured, platelet counts were 55.9 ± 15.4 × 10 9 /L (mean ± SEM, Table 1 ). Platelet counts were 18.8 ± 3. Figure 1C ) and P-selectin MFI in response to low (P <0.05) and high TRAP (P <0.001) ( Figure 1D ). There was a trend towards lower surface expression levels of CD41 on platelets from WAS/XLT patients compared to controls; however these differences were not statistically significant ( Figure 1E ). In contrast, the percentage of annexin V-positive events, as a
measure of procoagulant platelets and platelet-derived microparticles, showed no differences between WAS/XLT patients (n=6) and controls (n=7) ( Figure 1F ).
Mean platelet size is well known to be reduced in patients with WAS/XLT, 1 as reflected by the reduced FSC of platelets in the present study ( Figure 2A ). To determine whether differences in platelet surface activated GPIIb-IIIa and P-selectin between WAS/XLT patients and controls were due to differences in platelet size or were the result of reduced surface expression per unit area, platelet surface PAC1 binding and P-selectin expression were normalized to platelet surface CD41 fluorescence (a surrogate for platelet surface area). When platelet surface activated GPIIbIIIa and P-selectin were corrected for platelet size by CD41 MFI, no differences were seen between WAS/XLT patients vs. controls ( Figure 2B , C). These results indicate that platelet activation measured by PAC1 binding and P-selectin expression is proportional to platelet size in WAS/XLT.
Platelet surface markers of activation in WAS/XLT patients treated with eltrombopag
Platelet activation was re-assessed in three WAS/XLT patients who were on eltrombopag 20 -75 mg daily, with time on eltrombopag ranging from 1 to 21.5 months (Table 1 ). Eltrombopag treatment after these different time points significantly increased platelet counts in these patients from 18.3 ± 1.2 × 10 9 /L to 49.0 ± 11.0 × 10 9 /L (mean ± SEM; Figure 3A) . Also, the individual data show an increase in platelet count for each patient (data not shown); thus, eltrombopag produced more platelets in all three patients, independent of the time of drug treatment.
However, the presence of these new platelets did not result in an improvement in platelet activation, as measured by PAC1 binding, P-selectin expression and annexin V binding after agonist stimulation ( Figure 3B-F) , with the exception of high ADP-induced activated GPIIb-IIIa MFI ( Figure 3C ).
BLEEDING AND PLATELET COUNTS
Clinical Results: Five of 8 WAS/XLT patients (3 XLT and 2 WAS) who were on eltrombopag treatment for at least one month (1 adult, 4 children) were clinical responders, as evidenced by achieving at least one platelet count ≥ 50 × 10 9 /L and double the baseline count, and 6 of 8 had reduced bleeding symptoms ( Figure 4 , Table 2 ). Prior to eltrombopag treatment, 2 patients received frequent platelet transfusions, and a third patient reported frequent and severe episodes of epistaxes lasting 30 minutes or more. One responder had experienced an intracranial hemorrhage prior to eltrombopag, while another had failed hematopoietic stem cell transplantation (HSCT). On eltrombopag, responders and non-responders who experienced reduced bleeding reported that bruises, petechiae, and epistaxis resolved on their own. None of these patients experienced continued severe bleeding symptoms while on treatment ( Table 2) . Three WAS patients (1 adult) were non-responders to eltrombopag. Two had had at least one episode of intracranial hemorrhage prior to eltrombopag, one was splenectomized, and one had failed HSCT. Two patients discontinued eltrombopag due to lack of response, one of whom 
switched to romiplostim therapy with greater effect with the platelet count increasing to > 20 x 10 9 /L and having less bleeding. One continued eltrombopag because of a small reduction in bleeding symptoms combined with the lack of available alternative therapy. No patients experienced drug-related serious adverse events on eltrombopag.
ABSOLUTE IMMATURE PLATELET FRACTION
Absolute immature platelet fractions (AIPF) were measured in eltrombopag-treated patients (2 WAS, 3 XLT; post-eltrombopag data was unavailable for 2 patients) ( Figure 5 ). When compared to 7 age-matched chronic ITP patients responsive to eltrombopag, the 3 WAS/XLT patients had substantially and significantly lower baseline AIPFs and peak AIPFs. Increase in AIPF from baseline to peak, peak platelet count, and increase to peak platelet for the WAS/XLT patients were also significantly different from the ITP patients (two-tailed p-values <0.01 for all measurements, data not shown).
For
DISCUSSION
Bleeding is a major complication in patients with WAS/XLT, with 30% of patients facing lifethreatening bleeding, such as gastrointestinal and intracranial hemorrhages. 9 This bleeding tendency is primarily due to the thrombocytopenia observed in WAS/XLT patients; platelet counts are typically <10% of the number of circulating platelets in healthy persons. Given the apparently far higher incidence of serious bleeding in WAS/XLT than observed in comparably thrombocytopenic patients with ITP, two not mutually exclusive hypotheses have been entertained. One is that WAS platelets, absent in WASP, manifest intrinsic platelet function abnormalities. The second is that the microthrombocytopenia is responsible for the bleeding tendency. Thus, it is currently unclear whether, and if so to what degree, platelet dysfunction contributes to the bleeding diathesis in WAS/XLT. We therefore studied the activation state of circulating platelets in WAS/XLT patients with and without agonist stimulation ex vivo and compared these results with those obtained in healthy controls. The platelet surface expression of activated GPIIb-IIIa and P-selectin in response to agonists was lower in WAS/XLT patients compared to healthy controls ( Figure 1 ). However, after correction for surface area using CD41
as a surrogate, the surface expression of activated GPIIb-IIIa and P-selectin in WAS/XLT patients was not different from that of healthy controls (Figure 2 ). These results indicate that the reduced platelet activation observed in WAS/XLT platelets is primarily due to the small size of the platelets rather than to intrinsic platelet abnormalities.
Several previous studies have examined platelet function in WAS/XLT patients, but the findings have been variable and inconsistent. Some older studies report strongly reduced or absent aggregation in response to multiple agonists in WAS patients. 13;22;23 At the time of these studies there was less understanding of the mechanism of agonist-induced platelet activation and the genetic basis of WAS had not yet been unraveled. 3 One study reported that platelet aggregation was normal as were release mechanisms, but a moderate storage pool defect was present in XLT patients. 14 Another study with WAS patients showed slightly enhanced platelet aggregation and secretion from dense granules induced by collagen-related peptide and thrombin. 15 However, none of these previous platelet function studies took into account the smaller size of WAS/XLT platelets, which could have resulted in false interpretation of the data. Furthermore, the
thrombocytopenia that is present in WAS/XLT is well known to interfere with the interpretation of tests of platelet function studies -with the exception of flow cytometry. 12 The only previous flow cytometric study of platelet function in WAS/XLT which considered the smaller size of platelets in WAS/XLT, measured only normal sized platelets by electronic gating in a flow cytometer. 16 These normal-sized platelets in WAS showed reduced expression of GPIIb-IIIa and P-selectin after agonist stimulation compared to controls. However, unlike the present study, the mean age of healthy controls in this study 16 was 33 years and not age-matched to the WAS patients (mean age 2.7 years). Furthermore, in this study 16 platelet function was determined in platelet-rich plasma rather than whole blood (as was done in the present study), which may have affected the results by introducing artifactual platelet activation. Variations in study logistics might also explain different findings between studies with WAS/XLT patients. In our study patient recruitment and platelet activation analysis were performed at two different locations.
However a very short time after blood draw, aliquots were incubated with agonist and antibodies and samples were fixed before they were sent from the patient recruitment center in New York to the central laboratory in Boston where the analysis was performed. We have previously standardized this approach.
20;24-28
Our results show that the reduced platelet activation of WAS/XLT patients compared to agematched controls can be explained by the smaller size of WAS/XLT platelets, rather than an intrinsic difference in platelet activation ( Figure 2 
between patients were too large to observe statistically significant increases in the percentage of phosphatidylserine-positive microparticles and mean fluorescence ( Figure 1F ).
The relative contributions to thrombocytopenia of decreased platelet production and increased platelet destruction has not been completely resolved in WAS/XLT patients. The high rate of normalization of the platelet count by splenectomy in these patients implies that accelerated platelet destruction in the spleen plays an important role in the thrombocytopenia of WAS/XLT patients. 30 On the other hand, there are several studies demonstrating that platelet production in WAS appears to be impaired. 5;31-35 In the present study, compared to thrombocytopenic children with ITP also treated with eltrombopag, platelet production was not only decreased in WAS/XLT patients prior to treatment but the increase in AIPF in response to eltrombopag was also far less Current clinically-available therapeutic approaches other than platelet transfusion to increase the platelet count in WAS/XLT include splenectomy and HSCT. However, given the poor response to carbohydrate antigens in WAS/XLT, post-splenectomy pneumococcal sepsis has occurred at a higher rate than in other splenectomized conditions, e.g., ITP and hereditary spherocytosis. 
therapy. In XLT, a clinically less severe disorder than WAS, the optimal therapeutic approach is far less clear. 39 Our present data suggest that, while additional therapies are needed to address the immunodeficiency, infections, eczema, autoimmunity, and other XLT-related complications, a therapeutic trial of eltrombopag in XLT patients may be beneficial and may avoid a splenectomy (with its increased risk of post-splenectomy sepsis) and also avoid HSCT with its attendant mortality and substantial morbidity (e.g., graft-versus-host disease). 40 In XLT patients who respond to eltrombopag, it appears that it can be given indefinitely in anticipation of development of a future curative treatment with low morbidity and mortality. Successfully increasing the platelet count and thus reducing bleeding is important, but is not the only problem facing patients with WAS/XLT. In XLT patients, the risks of autoimmunity and development of malignancy are less than in WAS patients and thus an effective, safe treatment to reduce bleeding (by increasing the platelet count) has an important role in management of these patients.
Nonetheless, use of IVIG and antibiotics as anti-infective treatments are important in not only WAS but also certain XLT patients and complement the use of eltrombopag.
In addition to monitoring liver function tests, there are two areas of potential concern with eltrombopag: malignancy and marrow fibrosis. Leukemia is less of a risk for WAS/XLT patients than lymphoma. 
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